Biochemical characterization of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase from Leishmania (Viannia) and its evaluation as a drug target

Biomedica

Volumn 33, Issue 3, 2013, Pages 393-401

  Osorio, Edison ^a   Aguilera, Carolina ^a,b   Naranjo, Nelson ^a   Marín, Marcel ^a   Muskus, Carlos ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b Facultad de Ciencias Básicas   (Colombia)

Author keywords

Folic acid antagonists; Leishmania braziliensis; Tetrahydrofolate dehydrogenase; Thymidylate synthase

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; MULTIENZYME COMPLEX; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE-DIHYDROFOLATE REDUCTASE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; LEISHMANIA;

FOLIC ACID ANTAGONISTS; LEISHMANIA; MULTIENZYME COMPLEXES; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 84893487860     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v33i3.1434     Document Type: Article

References (38)

1. Lawn SD, Whetham J, Chiodini PL, Kanagalingam J, Watson J, Behrens RH, et al. New world mucosal and cutaneous leishmaniasis: An emerging health problem among British travellers. QJM. 2004;97:781-8. http://dx.doi.org/10.1093/qjmed/hch127
2. Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M. Cutaneous leishmaniasis: aAn increasing threat for travellers. Clin Microbiol Infect. 2005;11:343-6. http://dx.doi.org/10.1111/j.1469-0691.2004.01046.x
3. Scarisbrick JJ, Chiodini PL, Watson J, Moody A, Armstrong M, Lockwood D, et al. Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis. Travel Med Infect Dis. 2006;4:14-21. http://dx.doi.org/10.1016/j.tmaid.2004.11.002
4. Stark D, van Hal S, Lee R, Marriott D, Harkness J. Leishmaniasis, an emerging imported infection: Report of 20 cases from Australia. J Travel Med. 2008;15:351-4. http://dx.doi.org/10.1111/j.1708-8305.2008.00223.x
5. World Health Organization. Control of leishmaniasis. Geneva: Sixtieth World Health Assembly; 2007. Fecha de consulta: 10 de enero de 2012. Disponible en: http://www.who.int/gb/ebwha/pdf_files/WHA60/A60_10-en.pdf.
6. Cuervo P, de Jesús JB, Junqueira M, Mendoça-Lima L, Gonzáles LJ, Betancourt L, et al. Proteome analysis of Leishmania (Viannia) braziliensis by two-dimensional gel electrophoresis and mass spectrometry. Mol Biochem Parasitol. 2007;154:6-21. http://dx.doi.org/10.1016/j.molbiopara.2007.03.013
7. Osorio LE, Castillo CM, Ochoa MT. Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: Clinical characteristics. Am J Trop Med Hyg. 1998;59:49-52.
8. Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg. 2006;100:264-9.
9. Santos DO, Coutinho CE, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, et al. Leishmaniasis treatment -a challenge that remains: A review. Parasitol Res. 2008;103:1-10. http://dx.doi.org/10.1007/s00436-008-0943-2.
10. Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Glob Infect Dis. 2010;2:167-76. http://dx.doi.org/10.4103/0974-777X.62887
11. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist. 2012;2:11-9. http://dx.doi.org/10.1016/j.ijpddr.2012.01.003
12. Singh N, Kumar M, Kumar Singh R. Leishmaniasis: Current status of available drugs and new potential drug targets. Asian Pac J Trop Med. 2012;5:485-97. http://dx.doi.org/10.1016/S1995-7645(12)60084-4
13. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resist Updat. 2004;7:257-66. http://dx.doi.org/10.1016/j.drup.2004.07.002
14. Ivanetich KM, Santi DV. Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa. FASEB j.1990;4:1591-7.
15. Maganti L, Manoharan P, Ghoshal N. Probing the structure of Leishmania donovani chagasi DHFR-TS: Comparative protein modeling and protein-ligand interaction studies. J Mol Model. 2010;16:1539-47.http://dx.doi.org/10.1007/s00894-010-0649-0
16. Watkins, WM, Mberu EK, Winstanley PA, Plowe CV. The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today. 1997;13:459-64. http://dx.doi.org/10.1016/S0169-4758(97)01124-
17. Anderson AC. Targeting DHFR in parasitic protozoa. Drug Discov Today. 2005;10:121-8. http://dx.doi.org/10.1016/S1359-6446(04)03308-2
18. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54. http://dx.doi.org/10.1016/0003-2697(76)90527-3
19. Reche P, Arrebola R, Santi D, Pacanowska D, Ruiz L. Expression and characterization of the Trypanosoma cruzi dihydrofolate reductase domain. Mol Biochem Parasitol. 1996;76:175-85. http://dx.doi.org/10.1016/0166-6851(95)02557-X
20. Osorio E, Montoya G, Muñoz K, Arango G. Actividad antiplasmodial de alcaloides aporfínicos de Rollinia pittieri y Pseudomalmea boyacana (Annonaceae). Vitae. 2006;13:45-50.
21. Arrebola R, Olmo A, Reche P, Garvey EP, Santi DV, Ruiz-Pérez LM, et al. Isolation and characterization of a mutant dihydrofolate reductase-thymidylate synthase from methotrexate-resistant Leishmania cells. J Biol Chem. 1994;269:10590-6.
22. Scott DA, Coombs GH, Sanderson BE. Effects of methotrexate and other antifolates on the growth and dihydrofolate reductase activity of leishmania promastigotes. Biochem Pharmacol. 1987;36:2043-5. http://dx.doi.org/10.1016/0006-2952(87)90508-9
23. Berman JD, King M, Edwards N. Antileishmanial activities of 2,4-diaminoquinazoline putative dihydrofolate reductase inhibitors. Antimicrob Agents Chemother. 1989;33:1860-3. http://dx.doi.org/10.1128/AAC.33.11.1860
24. Hardy LW, Matthews W, Nare B, Beverley SM. Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways. Exp Parasitol. 1997;87:157-69.
25. Chowdhury SF, Villamor VB, Guerrero RH, Leal I, Brun R, Croft SL, et al. Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase. J Med Chem. 1999;42:4300-12. http://dx.doi.org/10.1016/j.bmc.2005.01.025
26. Zuccotto F, Brun R, Pacanowska DG, Pérez LMR, Gilbert IH. The structure-based design and synthesis of selective inhibitor of Trypanosoma cruzi dihydrofolate reductase. Bioorg Med Chem Lett. 1999;9:1463-8. http://dx.doi.org/10.1016/S0960-894X(99)00213-9
27. Zuccotto F, Zvelebil M, Brun R, Chowdhury SF, Lucrezia RD, Leal I, et al. Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase. Eur J Med Chem. 2001;36:395-405. http://dx.doi.org/10.1016/S0223-5234(01)01235-1
28. Chowdhury SF, Guerrero RH, Brun R, Ruiz-Pérez LM, Pacanowska DG, Gilbert IH. Synthesis and testing of 5-benzyl-2,4-diaminopyrimidines as potential inhibitors of leishmanial and trypanosomal dihydrofolate reductase. J Enzyme Inhib Med Chem. 2002;17:293-302.
29. Pez D, Leal I, Zuccotto F, Boussard C, Brun R, Croft SL, et al. 2,4-Diaminopyrimidines as inhibitors of leishmanial and trypanosomal dihydrofolate reductase. Bioorg Med Chem. 2003;11:4693-711. http://dx.doi.org/10.1016/j.bmc.2003.08.012
30. Khabnadideh S, Pez D, Musso A, Brun R, Ruiz-Pérez LM, González-Pacanowska D, et al. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase. Bioorg Med Chem. 2005;13:2637-49. http://dx.doi.org/10.1016 /j.bmc.2005.01.025
31. Gamarro F, Yu PL, Zhao J, Edman U, Greene PJ, Santi D. Trypanosoma brucei dihydrofolate reductase-thymidylate synthase: Gene isolation and expression and characterization of the enzyme. Mol Biochem Parasitol. 1995;72:11-22. http://dx.doi.org/10.1016/0166-6851(95)00059-A
32. Osorio E. Evaluación de la actividad antiparasitaria de extractos y compuestos alcaloidales de especies de la familia Annonaceae (tesis). Medellín: Universidad de Antioquia; 2005. p. 136-40.
33. Gangjee A, Qiu Y, Li W, Kisliuk RL. Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: Classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates. J Med Chem. 2008;51:5789-97. http://dx.doi.org/10.1021/jm8006933.
34. Osorio E, Robledo SM, Bastida j.Alkaloids with antiprotozoal activity. En: Cordell GA, editor. The alkaloids: Chemistry and biology. The Netherlands: Academic Press; 2008. p. 113-90.
35. Woo SH, Sun NJ, Cassady JM, Snapka RM. Topoisomerase II inhibition by aporphine alkaloids. Biochem Pharmacol. 1999;57:1141-5. http://dx.doi.org/10.1016/S0006-2952(99)00018-0
36. Hoet S, Stévigny C, Block S, Opperdoes F, Colson P, Baldeyrou B, et al. Alkaloids from Cassytha filiformis and related aporphines: Antitrypanosomal activity, cytotoxicity, and interaction with DNA and topoisomerases. Planta Med. 2004;70:407-13. http://dx.doi.org/10.1055/s-2004-818967
37. Wang J, Leblanc E, Chang CF, Papadopoulou B, Bray T, Whiteley JM, et al. Pterin and folate reduction by the Leishmania tarentolae H Locus short-chain dehydrogenase/reductase PTR1. Arch Biochem Biophys. 1997;342:197-202. http://dx.doi.org/10.1006/abbi.1997.0126
38. Vickers TJ, Beverley SM. Folate metabolic pathways in Leishmania. Essays Biochem. 2011;51:63-80. http://dx.doi.org/10.1042/bse0510063.